Bristol-Myers Squibb, Pfizer Unload Slew of Eliquis Infringement Cases
Bristol-Myers Squibb Co. and Pfizer Inc. on Monday filed a slew of patent infringement suits in Delaware to protect their patents for the successful drug Eliquis and halt the development of generic versions of the profitable blood thinner.
This premium content is reserved for Delaware Law Weekly subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now